Cargando…

Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

BACKGROUND: Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstrictor. The optimal albumin dose remains poorly characterized. This meta-analysis aimed to determine the impact of albumin dose on treatment outcomes. METHODS: Clinical studies of type 1 hepatorenal sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salerno, Francesco, Navickis, Roberta J., Wilkes, Mahlon M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660686/ https://www.ncbi.nlm.nih.gov/pubmed/26606982 http://dx.doi.org/10.1186/s12876-015-0389-9

Ejemplares similares

Albumin in Burn Shock Resuscitation: A Meta-Analysis of Controlled Clinical Studies
por: Navickis, Roberta J., et al.
Publicado: (2016)

Tetrastarch in cardiac surgery: error, confounding and bias in a meta-analysis of randomized trials
por: Navickis, Roberta J, et al.
Publicado: (2015)

No evidence of excess mortality in patients receiving human albumin: a meta-analysis of randomized controlled trials
por: Wilkes, MM, et al.
Publicado: (2001)

Mixed colloids and acute kidney injury: a case of selection bias?
por: Groeneveld, AB Johan, et al.
Publicado: (2015)

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021)

The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent
por: Afinogenova, Yuliya, et al.
Publicado: (2015)

Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

Pharmacological treatment of hepatorenal syndrome: a network meta-analysis
por: Wang, Li, et al.
Publicado: (2019)

Hypoalbuminemia in the acutely ill – risks and rationale for treatment: a meta-analysis
por: Navickis, RJ, et al.
Publicado: (2002)

Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment
por: Low, G., et al.
Publicado: (2015)

Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

A Review of Hepatorenal Syndrome
por: Subedi, Abinash, et al.
Publicado: (2021)

COVID-19 and hepatorenal syndrome
por: Wu, Henry H L, et al.
Publicado: (2022)

Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival
por: Heidemann, Jan, et al.
Publicado: (2015)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
por: Sanyal, A. J., et al.
Publicado: (2017)

Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects
por: Facciorusso, Antonio
Publicado: (2019)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Commentary: Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

Erratum: Metabolic syndrome and the hepatorenal reflex
Publicado: (2017)

Hepatorenal syndrome: Update on diagnosis and therapy
por: Acevedo, Juan G, et al.
Publicado: (2017)

Hepatorenal syndrome in children: a review
por: Liu, Priscila Menezes Ferri, et al.
Publicado: (2020)

Management of Hepatorenal Syndrome: A Review
por: Tariq, Raseen, et al.
Publicado: (2020)

Liver Kidney Crosstalk: Hepatorenal Syndrome
por: Nassar, Mahmoud, et al.
Publicado: (2021)

Can treatment with the molecular adsorbent recirculation system be the solution for type-1 hepatorenal syndrome?
por: Lavayssiere, L
Publicado: (2013)

Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials
por: Jacob, Matthias, et al.
Publicado: (2008)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival
por: Solé, Cristina, et al.
Publicado: (2019)

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
por: Mohamed, Mohamed M G, et al.
Publicado: (2021)

Combined Liver-Kidney Transplantation for Hepatorenal Syndrome
por: Kanubhai Sutariya, V., et al.
Publicado: (2015)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

Prognostic Markers in Patients with Ascites and Hepatorenal Syndrome
por: Nazal, Leyla, et al.
Publicado: (2011)

Optimal management of hepatorenal syndrome in patients with cirrhosis
por: Angeli, Paolo, et al.
Publicado: (2010)

Acute kidney injury and hepatorenal syndrome in cirrhosis
por: Gupta, Kapil, et al.
Publicado: (2021)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a4i5ba6tkd9orabeaqvjb3knc1